On Tuesday, Jefferies maintained its Buy rating on shares of Amgen (NASDAQ:AMGN) with a price target of $380.00. The firm's commentary focused on the latest data from Phase I of AMG-133, which involves additional measurements of bone mineral density (BMD) in patients with obesity. The data shows varying results, with the highest dose group experiencing some declines, while other dosage groups had increases in BMD. These fluctuations are noted as being part of the expected class effect for weight loss (WL) drugs.
The firm noted that the BMD changes are returning to normal levels, which is consistent with known effects of weight loss drugs on bone density. Amgen has previously discussed this aspect and has made the data public. According to Jefferies, the data's variability is not necessarily a cause for concern, as the company has anticipated and addressed these effects in its publications.
Amgen's study of AMG-133 is part of ongoing research into treatments for obesity, a significant health concern worldwide. The drug's impact on BMD is one of the many factors being monitored to ensure its safety and efficacy for potential users. The latest observations from the trial indicate a complex interaction between the drug and bone density, but Jefferies' analysis suggests that the overall effect falls within expected parameters.
The investment firm's reiteration of its Buy rating and price target suggests confidence in Amgen's handling of the drug's development process. The company's transparency in publishing data and addressing known drug class effects appears to have contributed to Jefferies' positive outlook on the stock.
Amgen's continued progress with AMG-133 and its implications for the treatment of obesity will likely remain a point of interest for investors and healthcare professionals alike. The current valuation by Jefferies indicates a belief in the potential success and market acceptance of the drug upon successful completion of its trial phases.
In other recent news, Amgen has reported a significant third-quarter growth, with revenues increasing 23% to $8.5 billion. This growth is largely attributed to double-digit sales growth in ten products, especially in the oncology and rare disease sectors, with the latter generating $1.2 billion. Cantor Fitzgerald has maintained its Overweight rating and $405.00 price target on Amgen, following the discovery of new data related to the company's drug candidate, MariTide.
The uncovered data reveals bone mineral density data from the Phase 1 study of MariTide, which could potentially impact the drug's progress. In terms of future expectations, Amgen anticipates total revenues for 2024 to range between $33.0 billion and $33.8 billion, and plans for increased investments in research and development and manufacturing, especially for MariTide.
Despite preparing for increased competition in the osteoporosis market, Amgen expressed confidence in long-term growth across diversified portfolios.
InvestingPro Insights
To complement Jefferies' positive outlook on Amgen (NASDAQ:AMGN), recent data from InvestingPro provides additional context for investors. Amgen's market capitalization stands at $160.57 billion, reflecting its significant position in the biotechnology sector. The company's revenue growth of 21.25% over the last twelve months and a 23.18% increase in quarterly revenue demonstrate strong financial performance, aligning with the potential of its drug pipeline, including AMG-133.
InvestingPro Tips highlight Amgen's consistent dividend history, having raised its dividend for 14 consecutive years. This track record of dividend growth, coupled with a current dividend yield of 2.8%, may appeal to income-focused investors alongside the company's growth prospects in the obesity treatment market.
It's worth noting that Amgen's P/E ratio of 37.88 suggests a premium valuation, which could be justified by the market's expectations for future growth from products like AMG-133. Investors seeking more comprehensive analysis can find 10 additional InvestingPro Tips for Amgen, offering deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.